Skip to content
Screener

Ligand Pharmaceuticals LGND Gross Profit

Discontinued — last reported Q3 '19

Gross Profit at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$265.21M-40.8%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$90.62M+9.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$54.21M+10.8%
Opko Health logo
Opko HealthOPK
$80.02M+62.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$38.14M+182%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$26.9M-5.9%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×—
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%—
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

$24.8Mtotal revenue−$3.1Mtotal cost of revenue=$21.66M

The source filing: Ligand Pharmaceuticals’s 10-K, filed February 24, 2021. Open the filing →

Filed
Feb 24, 2021, 5:03 PM EST
Fiscal year
FY2020
Accession
0000886163-21-000050

FAQ

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.